In Silico ADME and QSAR Studies on a Set of Coumarin Derivatives As Acetylcholinesterase Inhibitors Against Alzheimer’s Disease: CoMFA, CoMSIA, Topomer CoMFA, and HQSAR

Author(s): Uttam Ashok More*, Sameera Patel, Vidhi Rahevar, Malleshappa Ningappa Noolvi, Tejraj M. Aminabhavi, Shrinivas D. Joshi

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 6 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Alzheimer’s disease (AD) is increasingly being recognized as one of the lethal diseases in older people. Acetylcholinesterase (AChE) has proven to be the most promising target in AD, used for designing drugs against AD.

Methods: In silico studies, 2D- or 3D-QSAR like hologram QSAR (HQSAR), Topomer comparative molecular field analysis (Topomer CoMFA), comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) methods were used to generate QSAR models for acetylcholinesterase inhibitors.

Results: Acetylcholinesterase inhibitors used for the present study contain a series of 7- hydroxycoumarin derivatives connected by piperidine, piperazine, tacrine, triazole, or benzyl fragments through alkyl or amide spacer training set compounds were used to generate best model with a HQSAR q2 value of 0.916 and r2 value of 0.940; a Topomer CoMFA q2 value of 0.907 and r2 value of 0.959, CoMFA q2 value of 0.880 and r2 value of 0.960; and a CoMSIA q2 value of 0.865 and r2 value of 0.941. In addition, contour plots obtained from QSAR models suggested the significant regions that influenced the AChE inhibitory activity.

Conclusion: In light of these results, this study provides knowledge about the structural requirements for the development of more active acetylcholinesterase inhibitors. In addition, the predicted ADME profile helps us to find CNS active molecules, the obtained prediction compared with well-known AChE inhibitors viz., ensaculin, tacrine, galantamine, rivastigmine, and donepezil. Based on the knowledge obtained from these studies, the hybridization approach is one of the best ways to find lead compounds and these findings can be useful in the treatment of Alzheimer's disease.

Keywords: 7-Hydroxy coumarins, HQSAR, CoMFA, CoMSIA, topomer CoMFA, AChE inhibitors.

[1]
Gao H-M, Hong J-S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression Trends Immunol 2008; 29(8): 357-65.
[http://dx.doi.org/10.1016/j.it.2008.05.002] [PMID: 18599350]
[2]
Kril JJ, Halliday GM. 2001; 48: 167-217.
[3]
S Schneider L. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease. Dialogues Clin Neurosci 2000; 2(2): 111-28.
[PMID: 22033801]
[4]
Soreq H, Seidman S. Acetylcholinesterase--new roles for an old actor. Nat Rev Neurosci 2001; 2(4): 294-302.
[http://dx.doi.org/10.1038/35067589] [PMID: 11283752]
[5]
Enz A, Floersheim P. Cholinesterase Inhibitors: An Overview of their Mechanisms of ActionAlzheimer Disease: From Molecular Biology to Theraphy; Becker, RE; Giacobini, E; Barton, JM; Brown, M. Boston, MA 1997; pp. 211-5.
[6]
Brufani M, Filocamo L. Rational Design of New Acetylcholinesterase Inhibitors. 1997.
[7]
Radić Z, Reiner E, Taylor P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991; 39(1): 98-104.
[PMID: 1987454]
[8]
Rao J M, Raju B C, Srinivas P V, et al. 2012.
[9]
Tong W, Lowis DR, Perkins R, et al. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 1998; 38(4): 669-77.
[http://dx.doi.org/10.1021/ci980008g] [PMID: 9722424]
[10]
Glennon RA. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003; 46(14): 2795-812.
[http://dx.doi.org/10.1021/jm030030n] [PMID: 12825922]
[11]
Solis FJ, Wets RJ-B. Minimization by Random Search Techniques. Math Oper Res 1981; 6(1): 19-30.
[http://dx.doi.org/10.1287/moor.6.1.19]
[12]
Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988; 110(18): 5959-67.
[http://dx.doi.org/10.1021/ja00226a005] [PMID: 22148765]
[13]
Klebe G, Abraham U, Mietzner T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994; 37(24): 4130-46.
[http://dx.doi.org/10.1021/jm00050a010] [PMID: 7990113]
[14]
Klebe G. Comparative molecular similarity indices analysis: CoMSIA. Perspect Drug Discov Des 1998; 12(0): 87-104.
[http://dx.doi.org/10.1023/A:1017025803403]
[15]
Bush BL, Nachbar RB Jr. Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA. J Comput Aided Mol Des 1993; 7(5): 587-619.
[http://dx.doi.org/10.1007/BF00124364] [PMID: 8294948]
[16]
Dunn WJ, Wold S, Edlund U, Hellberg S, Gasteiger J. Multivariate structure-activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method. Quant. Struct.-. Act Relat 1984; 3(4): 131-7.
[http://dx.doi.org/10.1002/qsar.19840030402]
[17]
Geladi P. Notes on the history and nature of partial least squares (PLS) modelling. J Chemometr 1988; 2(4): 231-46.
[http://dx.doi.org/10.1002/cem.1180020403]
[18]
Kubinyi H. 3D QSAR in drug design. Theory Methods and Applications 1993; pp. 1281-306.
[19]
Lee JY, Doddareddy MR, Cho YS, et al. Comparative QSAR studies on peptide deformylase inhibitors. J Mol Model 2007; 13(5): 543-58.
[http://dx.doi.org/10.1007/s00894-007-0175-x] [PMID: 17333308]
[20]
Cramer RD, Bunce JD, Patterson DE. Frank, I.E. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies. Quant. Struct.-. Act Relat 1988; 7(1): 18-25.
[http://dx.doi.org/10.1002/qsar.19880070105]
[21]
Wold S. Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models. Technometrics 1978; 20(4): 397-405.
[http://dx.doi.org/10.1080/00401706.1978.10489693]
[22]
Alipour M, Khoobi M, Moradi A, et al. Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives. Eur J Med Chem 2014; 82: 536-44.
[http://dx.doi.org/10.1016/j.ejmech.2014.05.056] [PMID: 24941128]
[23]
Jalili-Baleh L, Forootanfar H, Küçükkılınç TT, et al. Design, synthesis and evaluation of novel multi-target-directed ligands for treatment of Alzheimer’s disease based on coumarin and lipoic acid scaffolds. Eur J Med Chem 2018; 152: 600-14.
[http://dx.doi.org/10.1016/j.ejmech.2018.04.058] [PMID: 29763808]
[24]
Moradi A, Faraji L, Nadri H, et al. Synthesis, docking study, and biological evaluation of novel umbellipherone/ hymecromone derivatives as acetylcholinesterase/butyrylchol-inesterase inhibitors. Med Chem Res 2018; 27(7): 1741-7.
[http://dx.doi.org/10.1007/s00044-018-2187-8]
[25]
Xie S-S, Wang X-B, Li J-Y, Yang L, Kong L-Y. Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer’s disease. Eur J Med Chem 2013; 64: 540-53.
[http://dx.doi.org/10.1016/j.ejmech.2013.03.051] [PMID: 23685572]
[26]
Clark M, Cramer RD, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem 1989; 10(8): 982-1012.
[http://dx.doi.org/10.1002/jcc.540100804]
[27]
Purcell WP, Singer JA. A brief review and table of semiempirical parameters used in the Hueckel molecular orbital method. J Chem Eng Data 1967; 12(2): 235-46.
[http://dx.doi.org/10.1021/je60033a020]
[28]
Burke TR Jr, Fesen MR, Mazumder A, et al. Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem 1995; 38(21): 4171-8.
[http://dx.doi.org/10.1021/jm00021a006] [PMID: 7473544]
[29]
Cramer RD III, Patterson DE, Bunce JD. Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 1989; 291: 161-5.
[PMID: 2726839]
[30]
Jilek RJ, Cramer RD. Topomers: a validated protocol for their self-consistent generation. J Chem Inf Comput Sci 2004; 44(4): 1221-7.
[http://dx.doi.org/10.1021/ci049961d] [PMID: 15272829]
[31]
QikProp. Schrödinger, LLC New York, NY, USA 2012.
[32]
Sun Q, Peng D-Y, Yang S-G, Zhu X-L, Yang W-C, Yang G-F. Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase. Bioorg Med Chem 2014; 22(17): 4784-91.
[http://dx.doi.org/10.1016/j.bmc.2014.06.057] [PMID: 25088549]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 6
Year: 2020
Page: [684 - 712]
Pages: 29
DOI: 10.2174/1570180816666190712095907
Price: $65

Article Metrics

PDF: 10
HTML: 1